



## Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 28, 2024

CHICAGO--(BUSINESS WIRE)--Feb. 28, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results and provide full-year 2024 guidance.

To pre-register for the conference call please use this link:

Registration Link: <https://www.netroadshow.com/events/login?show=71651ed6&confid=60623>. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, March 20, 2024, at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code 671547. In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit "Events" on investor relations page of the Company's website at [www.xerispharma.com](http://www.xerispharma.com).

### About Xeris Biopharma Holdings, Inc.

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke<sup>®</sup>, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis<sup>®</sup>, a proven therapy for primary periodic paralysis, and Recorlev<sup>®</sup> for the treatment of endogenous Cushing's syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol<sup>™</sup> and XeriJect<sup>®</sup>, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit [www.xerispharma.com](http://www.xerispharma.com), or follow us on [X](#), [LinkedIn](#) or [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240228184972/en/>

### Investor Contact

Allison Wey  
Senior Vice President, Investor Relations and Corporate Communications  
[away@xerispharma.com](mailto:away@xerispharma.com)

Source: Xeris Biopharma Holdings, Inc.